Creating new treatments for asthma
Development of Novel Immunoregulatory Therapeutics for Asthma
This study is exploring new ways to treat asthma by using a special approach that helps calm down the immune system, especially for people who haven't found relief with current treatments.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Biotherapeutics, INC. NIH-funded |
| Lab location | 1 site (Blacksburg, United States) |
| Project ID | NIH-10822467 on NIH RePORTER |
What this research studies
This research focuses on developing innovative therapies for asthma by targeting a new immunoregulatory pathway in immune and epithelial cells. The approach combines advanced computational modeling with experimental methods to create precision immunology products. The goal is to provide a more effective treatment option for patients, particularly those who do not respond well to current therapies. By manipulating regulatory T cells, the research aims to suppress inflammation associated with asthma and improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from asthma, particularly those with type 2 asthma or those who have not responded adequately to existing treatments.
Not a fit: Patients with asthma who respond well to current therapies or those with non-allergic asthma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective asthma treatments that significantly improve the quality of life for patients.
How similar studies have performed: While there have been unsuccessful attempts to target similar pathways in asthma treatment, the innovative approach of this research may offer new insights and potential breakthroughs.
Where this research is happening
Blacksburg, United States
- Biotherapeutics, INC. — Blacksburg, United States (Active)
Researchers
- Principal investigator: Bassaganya-Riera, Josep — Biotherapeutics, INC.
- Study coordinator: Bassaganya-Riera, Josep
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.